The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InFendX Technologies has officially signed a statement of work with Galenvs Sciences to initiate pilot-scale manufacturing of its proprietary liquid surface coating. This strategic partnership aims to transition the antimicrobial technology from lab-scale development to a scalable production process, marking a critical milestone toward full commercialization. The coating formulation has already demonstrated significant antimicrobial activity and durability while maintaining low manufacturing costs. Dr. Carolyn Myers, CEO of FendX, emphasized that this collaboration is essential for establishing a cost-effective manufacturing process ready for market entry. This move is expected to reduce execution risk and bring the company closer to its first phase of revenue generation. Investors are closely watching the transition as the company moves toward large-scale industrial application.